Sinovac back in compliance with Nasdaq listing rules

Sinovac Biotech Ltd. reported that it has regained full compliance with the Nasdaq Global Market’s listing requirements.

Accepted by SEC EDGAR 06/15/2026 - 06:20 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Sinovac Biotech Ltd. reported that it has regained full compliance with the Nasdaq Global Market’s listing requirements. Nasdaq’s Hearing Advisor notified the company in a letter dated June 10, 2026, confirming compliance with Listing Rule 5250(c)(1) after Sinovac filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026.

The company will remain under a Mandatory Panel Monitor under Listing Rule 5815(d)(4)(B) until May 20, 2027, as previously determined by the Nasdaq Hearing Panel. The hearing that Sinovac had applied for has been canceled following the compliance determination.

Insights

Regulatory & Listing Analyst

Sinovac has restored Nasdaq listing compliance but remains monitored until May 2027.

Sinovac Biotech Ltd. received a Nasdaq notification on June 10, 2026 confirming it regained compliance with Listing Rule 5250(c)(1). This followed the company’s filing of its Form 20-F for the year ended December 31, 2025 on June 5, 2026, resolving its reporting deficiency.

The company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027, as set out in the Hearing Panel’s prior compliance determination. This means Nasdaq will continue to oversee Sinovac’s ongoing adherence to listing standards, but the immediate delisting risk tied to the prior non-compliance has been addressed.

The cancellation of the previously scheduled hearing indicates that no further remedial actions are required at this time beyond maintaining timely and complete reporting. Future company filings and disclosures will show whether Sinovac continues to satisfy Nasdaq’s requirements throughout the monitoring period ending in 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒                   Form 40-F ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Nan Wang
	Name:	Nan Wang
	Title:	Chief Financial Officer

Date: June 15, 2026

1

Exhibit Index

Exhibit 99.1 Press Release

2

Exhibit 99.1

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements

BEIJING, China June 15, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the “Notification Letter”), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market’s listing requirements. As noted in the Hearing Panel’s May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027.

The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.

The Company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive^®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.

SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu^®), the world’s first H1N1 influenza vaccine (Panflu.1^®), and CoronaVac^®, the most widely used inactivated COVID-19 vaccine globally.

Beyond its marketed portfolio, the Company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.

With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the Company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.

For more information, please see the Company’s website at www.sinovac.com.cn or www.sinovac.com.

Contacts

Sinovac Biotech Ltd.
Helen Yang
Tel: +86-10-8279 9779
Email: ir@sinovac.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.9 KB